Revolution Medicines, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $602.6M | $108.5M |
| FY2022 | — | $685.2M | $161.4M |
| FY2023 | — | $1.83B | $696.1M |
| FY2024 | — | $2.27B | $543.1M |
| FY2025 | — | $1.63B | $383.7M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $602.6M | $108.5M |
| FY2022 | — | $685.2M | $161.4M |
| FY2023 | — | $1.83B | $696.1M |
| FY2024 | — | $2.27B | $543.1M |
| FY2025 | — | $1.63B | $383.7M |